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Prognosis for patients suffering from malignant glioma has not substantially improved. Specific immunotherapy as a novel treatment
concept critically depends on target antigens, which are highly overexpressed in the majority of gliomas, but the number of such
antigens is still very limited. SOX2 was identified by screening an expression database for transcripts that are overexpressed in
malignant glioma, but display minimal expression in normal tissues. Expression of SOX2 mRNA was further investigated in tumour and
normal tissues by real-time PCR. Compared to cDNA from pooled normal brain, SOX2 was overexpressed in almost all (9 out of 10)
malignant glioma samples, whereas expression in other, non-malignant tissues was almost negligible. SOX2 protein expression in
glioma cell lines and tumour tissues was verified by Western blot and immunofluorescence. Immunohistochemistry demonstrated
SOX2 protein expression in all malignant glioma tissues investigated ranging from 6 to 66% stained tumour cells. Human leucocyte
antigen-A*0201-restricted SOX2-derived peptides were tested for the activation of glioma-reactive CD8þ cytotoxic T lymphocytes
(CTLs). Specific CTLs were raised against the peptide TLMKKDKYTL and were capable of lysing glioma cells. The abundant and
glioma-restricted overexpression of SOX2 and the generation of SOX2-specific and tumour-reactive CTLs may recommend this
antigen as target for T-cell-based immunotherapy of glioma.
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Malignant glioma represents the most common type of primary
brain tumours in the United States (Hofman et al, 2006). Despite
aggressive treatment with surgical resection followed by radio-
therapy and chemotherapy, these tumours ultimately recur
(Butowski et al, 2006). The median survival of patients suffering
from glioblastoma multiforme (GBM), the highest-grade malignant
astrocytoma, has not improved significantly over the past decades,
remaining at about 12 months (Legler et al, 1999). The infiltrative
nature of the tumour, the impracticality of optimal resection and
the comparative intolerance of the normal brain for cytotoxic
therapies together lead to a 5-year survival rate that is below
2% (Surawicz et al, 1998). This extraordinary high morbidity
has triggered a desperate search for novel and more specific
therapeutic approaches.
The use of either antibody-based or T-cell-mediated immu-
notherapy to selectively kill remnant glioma cells that could not be
completely removed by surgery because of the infiltration of the
tumour into the surrounding brain tissue has received increasing
attention. Several animal models suggested that GBM may be
amenable to immune therapeutic approaches (Sampson et al, 1996;
Okada et al, 1998) and the identification of humoral as well as
cellular immune responses in brain tumour patients triggered
efforts to activate the immune system against glioma cells (Yu
et al, 2001; Ueda et al, 2004). Although some encouraging pilot
studies and clinical trials were reported, so far immunotherapeutic
approaches were obviously hampered by the lack of defined target
antigens (Ehtesham et al, 2004). Therefore, dendritic cells (DCs)
pulsed with crude tumour cell homogenates or undefined peptide
mixtures eluted from tumour cells were frequently used to
augment glioma-reactive CTLs (Rutkowski et al, 2004; Yu et al,
2001, 2004; Yamanaka et al, 2003, 2005). However, to reduce the
potential risk of destructive autoimmune reactions, it seems
favourable to use groups of well-defined human leucocyte antigen
(HLA) class I binding peptides derived from glioma-associated
antigens that have been demonstrated to serve as target structures
for T cells rather than introducing undefined mixtures of antigens
to DCs.
To identify novel genes selectively expressed in malignant
gliomas and to increase the very limited number of characterised
glioma-associated CTL epitopes, we screened a large DNA chip-
based expression database (Weigle et al, 2004). We found that the
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stranscription factor SOX2 was overexpressed in the majority of
GBM samples whereas expression in normal brain and other non-
malignant tissues was almost negligible.
SOX (SRY-like HMG box) genes represent a family of transcrip-
tional cofactors implicated in the control of diverse developmental
processes (Wegner, 1999). So far, more than 20 Sox genes have
been described in mammals and are divided into six distinct
groups according to their HMG-box homology (Schepers et al,
2002). Sox genes exhibit highly dynamic expression patterns
during development of diverse tissues and cell types, especially
during embryogenesis. In early stages of mouse and chicken
embryonic development, Sox1–3 are highly expressed within the
CNS and are downregulated as neural cells exit the cell cycle and
start to differentiate (Uwanogho et al, 1995; Kamachi et al, 2000).
In humans, SOX2 mutations cause bilateral anophthalmia, a rare
and severe form of malformation of the eye (Fantes et al, 2003). A
number of SOX genes are amplified or upregulated in different
tumours and tumour cell lines (reviewed in Dong et al, 2004).
In the present study, we demonstrated the selective over-
expression of SOX2 in the vast majority of malignant gliomas on
the mRNA level as well as on the protein level. In immunohisto-
chemical analyses, all GBM specimens investigated were positive
for SOX2 protein, whereas SOX2 was not detectable in normal
cortex. In addition, we identified an HLA-A*0201-restricted
peptide derived from SOX2, which proved to be effective in
activating tumour-directed CTL responses.
MATERIALS AND METHODS
Dot blot analysis
A 112bp fragment of the SOX2 cDNA corresponding to nt 1433–
1544 of GenBank sequence NM_003106 was amplified from GBM
cDNA with the primers SOX2_N3 (50-AAATGGGAGGGGTG
CAAAAGAGGAG-30) and SOX2_C3 (50-CAGCTGTCATTTGCT
GTGGGTGATG-30) using the following thermal profile: 951C for
5min; 40 cycles: 951C for 30s, 701C for 30s, 681C for 30s followed
by a final extension at 681C for 5min. The PCR product was cloned
into pCRII-TOPO (Invitrogen, Karlsruhe, Germany) and se-
quenced. The insert was isolated after EcoRI digestion, labelled
with
32P (Megaprime DNA labelling system; Amersham Bios-
ciences, Freiburg, Germany) and hybridised to a Human Multiple
Tissue Expression (MTE) Array 2 (BD Clontech, Heidelberg,
Germany). Hybridisation was performed according to the provi-
der’s instructions using 2.1 10
6c.p.m.ml
 1 of the radioactively
labelled probe, and signals were visualised by phosphoimaging
(Amersham Biosciences).
Brain tumour patients, tissue samples and cell lines
Primary tumour samples were obtained from brain tumour
patients with informed consent and were intraoperatively frozen
in liquid nitrogen (for RNA isolation) or fixed in 4% formaldehyde
(for histology). For immunohistochemical analysis of SOX2
expression in normal cortices, tissue samples from autopsies
verified to be free of disease were obtained from the Institute of
Neuropathology, University Hospital Muenster (Muenster, Germany).
Tissue specificity of mRNA expression was analysed by a quan-
titative PCR assay (see below) in three panels of normalised cDNAs
derived from 16 normal adult tissues (Human MTC Panels I and
II) and eight fetal tissues (Human Fetal Panel; all BD Clontech). In
these panels, cDNA is pooled from several Caucasian individuals
for each tissue type, including normal brain. The cDNA sample
‘glioma BC’ was from Biocat (Biocat GmbH, Heidelberg, Germany)
and was characterised as a glioma from a male patient (catalogue
no. C8235534, lot no. A605336).
The HLA-A*0201-positive mutant cell line T2, the chronic
myelogenous leukaemia cell line K562 and the glioma cell line
U373 (all from American Type Culture Collection, Manassas, VA,
USA) were cultured according to the provider’s instructions. The
melanoma cell line 93.04A12.1 was kindly provided by Dr CJM
Melief (University Hospital, Leiden, The Netherlands) and the
glioma cell line U343 was a generous gift from Dr H Fischer
(German Cancer Research Centre, Heidelberg, Germany). The
HLA-A2-positive primary GBM cell preparations DD-HT4 and
DD-HT6559 were maintained in DMEM supplemented with 20%
FCS, 100Uml
 1 penicillin, 100mgml
 1 streptomycin, 4% (vv
 1)
non-essential amino acids (Biochrom, Berlin, Germany), and
50mgml
 1 gentamycin.
RNA isolation and cDNA synthesis from tissue samples
and cell lines
Total RNA was extracted by standard procedures (TriPure
Reagent; Roche Diagnostics, Mannheim, Germany) and treated
with DNase I (Amersham Biosciences). As SOX2 is a single-exon
gene, absence of traces of genomic DNA was checked by PCR
before reverse transcription using b-actin-specific primers
Act_N1 (50-GCCGTCTTCCCCTCCATCGTG-30)/Act_C1 (50-GGAG
CCACACGCAGCTCATTGTAGA-30) with the thermal profile: 951C
for 3min; 35 cycles: 951C for 30s, 701C for 30s, 681C for 30s
followed by one round at 681C for 7min. The cDNA synthesis was
performed using 1mg of total RNA and oligo-dT primers in a
standard 20-ml reaction (Advantage RT-for-PCR Kit; BD Clontech).
Quantitative reverse transcription-PCR
Tissue specificity of SOX2 mRNA expression was analysed by a
quantitative light cycler (LC)-based PCR assay screening panels of
normalised cDNAs derived from 16 normal adult tissues (Human
MTC Panels I and II) and eight fetal tissues (Human Fetal Panel;
all BD Clontech) as well as cDNAs from tumour samples and cell
lines. The SOX2 mRNA quantity was determined by an SYBR
Green I-based real-time PCR protocol (LC – FastStart DNA Master
SYBR Green I; Roche Diagnostics) using the primer pairs
SOX2_N3/SOX2_C3 (see above). The PCR protocol for the SOX2
LC assay consisted of a pre-denaturation step (10min at 951C) and
40 amplification cycles (15s at 951C, 5s at 701C, 12s at 721C).
Specificity of the assay was checked by cloning and sequencing of
the PCR product and by melting curve analysis. To quantify the
transcript levels in specimens from brain tumour patients as well
as in the cell lines U373 and U343, 2ml of the 1:5 diluted cDNA
products was used for amplification with primer pair SOX2_N3/
SOX2_C3.
The amount of SOX2 transcripts was normalised to the quantity
of b-actin transcripts. SYBR Green I-based quantification of
b-actin was performed using the primers Act_N1 (50-GCC
GTCTTCCCCTCCATCGTG-30) and Act_C1 (50-GGAGCCACACGC
AGCTCATTGTAGA-30) applying the same PCR protocol as used
for SOX2.
Serial dilutions of plasmid DNA containing the SOX2 and
b-actin fragments over eight log scales (10
1–10
8 molecules per
capillary) were used as internal template standards (calculation via
LC quantification software version 3.5; Roche Diagnostics). Each
determination was carried out twice for each cDNA sample as
independent PCR runs and molecule ratios of SOX2 to b-actin
transcripts were calculated from the mean values.
Indirect immunofluorescence analysis
The glioma cell lines U373 and U343, the primary GBM cell
preparations DD-HT4 and DD-HT6559 as well as the melanoma
cell line 93.04A12.1 were grown on cover slides and fixed in
ice-cold paraformaldehyde for 20min. After washing in
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sphosphate-buffered saline (PBS), cells were permeabilised with 1%
sodium citrate/0.1% Triton X-100 and washed three times with
PBS containing 0.1% bovine serum albumin (BSA). Cells were
incubated for 1h at room temperature with monoclonal anti-SOX2
antibody (MAB2018, R&D Systems, Wiesbaden, Germany, dilution
1:200). After washing again with PBS/0.1% BSA, the cells were
incubated for 1h at room temperature with Cy3-conjugated anti-
mouse IgG (stock solution, 1:50 diluted, as recommended by the
supplier, Dianova, Hamburg, Germany). After intensive washing
with PBS the DNA was counterstained with Hoechst33342. Cells
were examined by fluorescence microscopy (Olympus IX70,
Hamburg, Germany).
Immunoblot analysis
For protein analysis of SOX2 expression in the melanoma cell line
93.04A12.1 and the glioma cell lines U373 and U343, total protein
lysates were prepared. Equal amounts of protein samples were
subjected to electrophoresis and blotted onto PVDF membranes
(PALL, Dreieich, Germany). SOX2 immunostaining was performed
with the monoclonal antibody MAB2018. Equal loading of protein
samples was confirmed by probing the blotted PVDF membranes
with an anti-a-tubulin antibody (clone DM 1a, diluted 1:500;
Sigma, Taufkirchen, Germany). The secondary goat anti-mouse
antibody coupled to horseradish peroxidase (both diluted 1:2500,
Dako, Hamburg, Germany) was visualised by using 3,30-diamino-
benzidine (DAB) (Sigma).
Immunohistochemistry of glioma tissue
Immunohistochemistry was performed on paraffin-embedded
human tumour tissue, diagnosed as glioblastoma (grade IV
astrocytoma; WHO), according to the World Health Organization
Classification (Kleihues and Cavenee, 2000). Paraffin-embedded
cortex tissue from autopsies without pathological findings in the
brain served as controls. Two micrometer paraffin sections were
treated with Target Retrieval Solution pH 9.0 (Dako) for 35min in
a steamer for unmasking epitopes. The anti-SOX2 antibody
MAB2018 was used in a concentration of 10mgml
 1 and incubated
overnight at 41C. Detection was performed with a biotinylated
secondary anti-mouse IgG antibody BA-2001 (diluted 1:100,
Vector Laboratories, Burlingame, CA, USA), using the avidin–
biotin–peroxidase technique with DAB (Dako) as chromogen.
Tissue was counterstained with haematoxylin. The proportion of
SOX2-positive cells was determined by counting all cell nuclei
as well as nuclei stained for SOX2 in three randomly selected
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Figure 1 Dot blot analysis of SOX2 mRNA expression pattern in normal tissues. A 112bp cDNA fragment of the SOX2 transcript was radioactively
labelled and hybridised to the human MTE Array 2 that provides poly(A)
þ RNA from 58 human adult tissues, eight tumour cell lines and seven human fetal
tissues normalised to eight housekeeping genes. Strong hybridisation signals were revealed only in fetal brain. A1, whole brain; B1, cerebral cortex; C1, frontal
lobe; D1, parietal lobe; E1, occipital lobe; F1, temporal lobe; F1, paracentral gyrus of the cerebral cortex; H1, pons; A2, cerebellum left; B2, cerebellum right;
C2, corpus callosum; D2, amygdala; E2, nucleus caudatus; F2, hippocampus; G2, medulla oblongata, H2, putamen; B3, nucleus accumbens, C3, thalamus; E3,
spinal cord; A4, heart; B4, aorta; C4, atrium left; D4, atrium right; E4, ventricle left; F4, ventricle, right; G4, interventricular septum; H4, apex of the heart; A5,
oesophagus; B5, stomach; C5, duodenum; D5, jejunum; E5, ileum; F5, ilocaecum; G5, appendix; H5, colon ascendens; A6, colon transversum; B6, colon
descendens; C6, rectum; A7, kidney; B7, skeletal muscle; C7, spleen; D7, thymus; E7, peripheral blood leucocyte; F7, lymph node; G7, bone marrow; H7,
trachea; A8, lung; B8, placenta; C8; bladder; D8, uterus; E8, prostate; F8, testis; G8, ovary; A9, liver; B9, pancreas; C9, adrenal gland; D9, thyroid gland; E9,
salivary gland; A10, leukaemia, HL-60; B10, HeLa S3; C10, leukaemia, K-562; D10, leukaemia, MOLT-4; E10, Burkitt’s lymphoma, Raji; F10, Burkitt’s
lymphoma, Daudi; G10, colorectal adenocarcinoma, SW480; H10, lung carcinoma, A549; A11, fetal brain; B11; fetal heart; C11, fetal kidney; D11; fetal liver;
E11, fetal spleen; F11, fetal thymus; G11, fetal lung.
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shigh-power fields (¼400-fold magnification) in the tumour core
of each sample.
Epitope prediction and peptide synthesis
Potential HLA-A*0201 ligands were selected from the amino-acid
sequence of SOX2 using a matrix pattern suitable for the
calculation of peptides fitting to an HLA-A*0201 motif (Rammensee
et al, 1999); http://www.syfpeithi.de). The three highest scoring
peptides were synthesised as described previously (Kiessling
et al, 2002).
Competition assay
Binding studies of potential HLA-A*0201-fitting peptides were
carried out using the B-cell line JY and a fluorescence-based
competition assay, essentially as described (Van der Burg et al,
1995), but without performing acid strip. Reporter peptide was
ILK(FITC)EPVHGV from HIV-1 reverse transcriptase and positive
control was YLLPAIVHI from RNA helicase p72. Fluorescence
intensities were recorded by flow cytometry.
In vitro generation of SOX2-specific CD8þ cytotoxic
T lymphocytes
Briefly, peripheral blood mononuclear cells were prepared from
blood samples of healthy donors by Ficoll–Hypaque (Biochrom,
Berlin, Germany) density centrifugation. Monocytes were isolated
by immunomagnetic cell separation with an anti-CD14 antibody
coupled to paramagnetic microbeads (Miltenyi Biotech, Bergisch
Gladbach, Germany) according to the manufacturer’s instructions.
Mature monocyte-derived DCs were generated as described
previously (Kiessling et al, 2002). To generate SOX2-specific CTLs,
mature DCs were pulsed with the SOX2-derived peptides 60029,
60030 and 60031 at a concentration of 20mgml
 1 of each peptide
in serum-free RPMI 1640 medium for 3h. After washing, 2 10
5
peptide-loaded DCs were co-cultured with 2 10
6 immunomag-
netically isolated CD8þ T cells per well of a 24-well tissue culture
plate (Greiner, Frickenhausen, Germany). T cells were cultured in
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Figure 2 Real-time PCR analysis of SOX2 expression in normal adult and fetal tissues and in brain tumours. (A) The tissue specificity of SOX2 mRNA was
determined by an SYBR Green I-based quantitative PCR assay in cDNA samples derived from 16 different pooled human adult tissues and eight different
pooled human fetal tissues. The amount of SOX2 transcripts was normalised to the quantity of transcripts of the housekeeping gene b-actin. High transcript
levels of SOX2 were found only in pooled fetal brain, whereas transcripts levels detected in adult brain, testis and skeletal muscle, the adult tissues with
highest SOX2 expression, were 16.5-, 52.9- and 54.1-fold lower, respectively (see insets). (B) The same assay was applied for the quantification of SOX2
transcripts in brain tumours. SOX2 was upregulated in almost all (nine out of 10) GBM samples, with eight of the samples displaying more than five-fold
overexpression compared to pooled normal adult brain cDNA. The pooled adult brain sample from (A) is inserted for comparison. The sample marked ‘BC’
is commercially available from Biocat (see Materials and Methods). The results represent the means of two independent LC runs, bars indicate s.e. GBM,
glioblastoma multiforme.
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s2ml RPMI 1640 medium per well supplemented with 10% human
serum (CCpro, Neustadt, Germany), 100Uml
 1 interleukin-2 (IL-
2) and 10ngml
 1 IL-7 (both from Strathmann Biotech, Hannover,
Germany). Seven days later, cultures were washed and restimu-
lated with peptide-loaded DCs at a responder to stimulator ratio of
5:1. After three rounds of weekly restimulation, the cultures were
tested for the presence of SOX2-specific CTLs.
Chromium release assay
Cytotoxic activity of the in vitro-stimulated CTLs was tested
against T2 cells loaded with the individual SOX2-derived peptides
or an irrelevant HLA-A*0201-binding peptide from HIV-1 reverse
transcriptase at a concentration of 50mgml
 1, the glioma cell lines
U343, U373, the primary GBM cell preparations DD-HT4 and DD-
HT6559, the melanoma cell line 93.04A12. 1, and K562 cells in a 4h
standard
51Cr-release assay as described previously (Kiessling et al,
2002). The HLA-A2 restriction of CD8þT-cell-mediated lysis
was evaluated at an effector cell to target cell ratio of 30:1 in the
presence of the monoclonal anti-HLA-A2 antibody BB7.2 or an
isotype-matched control antibody (BD Biosciences Pharmingen,
Heidelberg, Germany) at a final concentration of 10mgml
 1.
RESULTS
Identification of SOX2 as glioma-associated by analysis of DNA
chip data and expression quantification by real-time PCR
By screening the Affymetrix DNA chip-based GeneExpress
s
database for genes overexpressed in GBM (Weigle et al, 2005),
we identified the chip element 33109_f_at representing SOX2. The
transcription factor SOX2 was found to be overexpressed in the
majority of GBM samples and other brain tumours, whereas
expression in normal brain and other non-malignant tissues was
almost negligible (data not shown). A 112bp fragment of SOX2
cDNA was radioactively labelled and subsequently hybridised to an
MTE array representing pooled mRNA samples from 58 adult
human tissues, eight human cell lines and seven fetal human
tissues. Expression was detected exclusively in fetal brain
(Figure 1), whereas all other tissues, especially normal adult brain,
were SOX2 negative.
The expression of SOX2 in different normal tissues and tumour
specimens was thoroughly quantified with a sensitive real-time
PCR method. Transcript quantities were determined in a panel of
16 human adult tissues representing major organs as well as in a
panel of eight different fetal tissues (Figure 2A). To allow direct
comparison of expression levels, the results were normalised to the
transcript number of the housekeeping gene b-actin. Quantitative
PCR verified high expression of SOX2 in fetal brain (0.33
transcripts per b-actin transcript). In addition, minor expression
in adult brain, skeletal muscle, testis and small intestine was
detectable. The expression levels in these adult organs were 16.5-,
54.1-, 52.9- and 95.8-fold lower, respectively, when compared to
fetal brain (Figure 2A, left inset). Regarding additional fetal organs,
expression was highest in fetal lung and fetal kidney with 0.013
and 0.004 transcripts SOX2 per b-actin transcript, respectively
(Figure 2A, right inset).
To quantify SOX2 expression in GBMs and in brain tumour cell
lines, the amount of transcripts was determined in nine tumour
specimens from GBM patients from the Department of Neuro-
surgery and in one commercially available sample from a
malignant glioma patient by real-time PCR. In addition, the cell
lines U343, U373 and 93.04A12.1 were tested for SOX2 expression
(Figure 2B). Expression of SOX2 was upregulated in almost all (9
out of 10) samples as compared to cDNA from pooled normal
brain. In 80% of the tumour specimens (8 out of 10), SOX2
was overexpressed by more than five-fold, and in 40% of the
samples (4 out of 10), SOX2 was upregulated 20-fold or higher
(Figure 2B). U343, U373 and the melanoma line 93.04A12.1
expressed 0.6102, 0.4258 and 0.0001 transcripts SOX2 per
transcript b-actin, respectively.
Overexpression of SOX2 protein in tumour cells and GBM
tissue
To confirm that the relative amount of SOX2 mRNA is translated
into appropriate protein levels, we performed indirect immuno-
fluorescence analyses of U343 and U373 glioma cells as well as of
93.04A12.1-melanoma cells using a monoclonal anti-SOX2-anti-
body. As expected from the results of the quantitative mRNA
analyses, SOX2 protein was not detected in 93.04A12.1-melanoma
cells (Figure 3A and B) but was found predominantly in the nuclei
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Figure 3 SOX2 protein expression in the glioma cell lines U343 and
U373. Indirect immunofluorescence analyses of SOX2 expression. (A)
93.04A12.1 melanoma cells; (C) U343 and (D) U373 glioma cells.
Predominant nuclear SOX2 expression was detected only in the glioma
cells. (B, D and F) Appropriate counterstaining of cell nuclei with
Hoechst33342. (G and H) Western blot analysis of total protein lysates
from 93.04A12.1-melanoma cells (lane 1); U343 (lane 2) and U373 glioma
cells (lane 3). (G) SOX2 was detected only in lysates of glioma cell lines.
(H), equal loading of the gels was confirmed by using a monoclonal
antibody against a-tubulin.
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sof U343 and U373 glioma cells (Figure 3C–F). Additional Western
blot analyses confirmed the expression of SOX2 in lysates of U343
and U373 cells (Figure 3G and H).
Furthermore, we investigated GBM tissue from 11 patients for
expression of SOX2 protein in tumour cells in situ, using
immunohistochemistry. SOX2 was detected in all glioblastoma
specimens. The number of positive tumour cells differed between
individual cases, ranging from 6 to 66% in the central tumour core
(Figure 4A). Independent of the percentage of positive cells, SOX2
appeared as strong staining, restricted to the nuclei of glioblastoma
cells (Figure 4B). Other structures of the tumour, like blood
vessels, were negative for SOX2. SOX2 could not be detected in
cortex areas, which were not affected by tumour cell invasion, or in
cortex tissue obtained from four control cases without brain
tumours or other pathological findings in the brain (Figure 4C).
The primary GBM cell preparations DD-HT4 and DD-HT6559 were
positive for SOX2 protein expression (Figure 4D–G).
Identification of a naturally processed T-cell epitope
derived from SOX2
To investigate the potential of SOX2 as a target antigen for CTLs,
the amino-acid sequence of SOX2 was screened for peptides
predicted to bind to HLA-A*0201 representing the most frequent
HLA-A allele in Caucasians by using the SYFPEITHI software
(Table 1). The three highest scoring peptides fulfilling these
criteria were synthesised and analysed for their binding affinity to
HLA-A*0201 by a competition assay using peptide YLLPAIVHI
Table 1 Prediction of HLA-A*0201-restricted SOX2-derived peptides
and determination of binding affinities by a competition assay
Peptide Position
a Sequence MW Length
b Score rBA (%)
c
60029 275–283 SMYLPGAEV 965.5 9 26 97.2
60030 131–139 LLAPGGNSM 858.4 9 25 80.0
60031 118–127 ALSPASSRSV 1239.7 10 24 43.3
Abbreviations: MW¼molecular weight; rBA¼relative binding affinity.
aThe given
numbers indicate the position of the peptide in the amino acid sequence of SOX2.
bNumber of amino acids.
cThe relative binding affinities were determined by
comparing the inhibition of the reporter peptide binding by the analysed peptides in
relation to the inhibition obtained with a positive control peptide, which was set as
100%. The positive control peptide was YLLPAIVHI from RNA helicase p72 and
the reporter peptide was ILK(FITC)EPVHGV from HIV-1 reverse transcriptase. All
peptides were used at a concentration of 10mM.
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C)EPVHGV from HIV-1 reverse transcriptase as reporter peptide.
Binding affinities were classified as strong when the binding of a
reporter peptide was inhibited by 75–100% with respect to
inhibition of the reporter peptide binding by a positive control
peptide, as intermediate when the inhibition was 50–74% and as
weak when the inhibition was 25–49%. The peptides 60029 and
60030 bound with high affinity, whereas the peptide 60031
displayed a weak affinity (Table 1). All three peptides were used
for the in vitro stimulation of CD8þ T lymphocytes.
CD8þ T lymphocytes isolated from the blood of two healthy
donors were weekly stimulated with autologous DCs pulsed with a
cocktail of the peptides 60029, 60030 and 60031. After four
stimulation cycles, T cells were tested for the presence of peptide-
specific CTLs by chromium-release assays. Only peptide 60031
induced specific CTLs in both donors as shown by the specific lysis
of T2 cells loaded with this peptide (Figure 5A). Unloaded T2 cells
and T2 cells pulsed with a control peptide from HIV reverse
transcriptase were only marginally lysed (Figure 5A). To determine
whether peptide 60031 originates from intracellular processing of
the SOX2 protein and is presented on the surface of tumour cells,
the peptide-specific T cells were tested against the HLA-A2-
positive glioma cell lines U343 and U373 expressing SOX2. The
generated CTLs efficiently lysed cells of all glioma cell lines,
whereas only marginal lysis was observed when the SOX2-negative
melanoma cell line 93.04A12.1 expressing HLA-A2 was used as a
control (Figure 5B and C). In addition, we analysed the cytotoxic
activity of the CTLs against the SOX2-positive primary GBM cell
preparations DD-HT4 and DD-HT6559 expressing HLA-A2 as
determined by PCR and FACS analysis (data not shown). As
demonstrated (Figure 5B and C), CTLs of both donors markedly
lysed the primary GBM cell preparations. These results demonstrate
the autochtonous generation and presentation of the peptide 60031 by
glioma cells. Natural killer cell-like activity was excluded by the failure
of the peptide 60031-activated T-cell populations to lyse K562 cells
( F i g u r e5 Ba n dC ) .A si l l u s t r a t e di nF i g u r e5 D ,t h er e c o g n i t i o no f
U343, U373, DD-HT4 and DD-HT6559 glioma cells was restricted to
HLA-A2 as shown by a significant reduction of lytic activity in the
presence of a monoclonal anti-HLA-A2 antibody.
DISCUSSION
Immunotherapy represents a promising treatment option to
improve the clinical outcome of patients suffering from malignant
glioma. In this context, it has been documented that four out of 12
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Figure 5 (A) In vitro generation of cytotoxic effector T cells specifically recognising the SOX2-derived peptide 60031. Purified CD8þ T lymphocytes of
healthy donors were weekly stimulated by SOX2 peptide-pulsed autologous DCs. After four stimulations, T-cell cultures were tested for the activation of
peptide-specific CTLs. The stimulated T cells were added to 3 10
3 peptide-pulsed,
51Cr-labelled T2 target cells per well at an effector cell to target cell
ratio of 20:1. Unloaded T2 cells and T2 cells pulsed with an irrelevant peptide from HIV reverse transcriptase served as controls. The results represent the
mean values of triplicate determinations, bars indicate s.e.m. (B and C) SOX2-specific lysis of glioma cells by in vitro-generated cytotoxic effector cells. After
four rounds of stimulation activated CD8þ T cells from the two donors were co-cultured with
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spatients with newly diagnosed glioma who were treated with
adoptive transfer of ex vivo-activated T lymphocytes showed
partial regression of the tumour (Plautz et al, 2000). In patients
with recurrent malignant gliomas, the local administration of
in vitro-expanded tumour-reactive T cells resulted in complete or
partial tumour regressions (Tsuboi et al, 2003). In addition,
clinical trials revealed that DCs loaded with tumour surface-eluted
peptides or tumour lysate efficiently augment tumour-reactive
CTLs and intratumoral T-cell infiltration (Yu et al, 2001, 2004; Liau
et al, 2005). Further data demonstrated that DC administration
results in stable disease, minor or partial clinical responses as well
as prolonged survival time (Yamanaka et al, 2003, 2005; Yu et al,
2004). Because activation of T cells against undefined mixtures of
antigens generally bears the potential risk to induce destructive
autoimmune reactions, the identification of well-characterised
HLA class I binding peptides derived from glioma-associated
antigens that serve as target structures for T cells is warranted.
However, the number of glioma-associated proteins known to
elicit T-cell responses is rather limited. So far, T-cell epitopes
derived from SART-1 and -3 (Imaizumi et al, 1999; Murayama
et al, 2000), IL-13 receptor a2 chain (Okano et al, 2002), ADP-
ribosylation factor 4-like (ARF4L) (Nonaka et al, 2002), UDP-Gal:
betaGlcNAc beta1, 3-galactosyltransferase, polypeptide 3 (GALT3)
(Tsuda et al, 2002), AIM-2 (Liu et al, 2004a), EphA2 (Hatano et al,
2005) and the type III variant of the epidermal growth factor
receptor (EGFRvIII) (Wu et al, 2006) have been described. In
addition, it has been shown that HER-2, gp100, MAGE-1 and TRP-
2 were expressed in glioma and were recognised by CTLs (Liu et al,
2003, 2004b). However, the suitability of some candidates for
specific immunotherapy of glioma is limited. Thus, ARF4L and
GALT3 were markedly expressed in various normal tissues
(Nonaka et al, 2002; Tsuda et al, 2002) bearing the potential risk
of autoimmune reactions. In addition, gp100, MAGE-1, TRP-2 and
EGFRvIII were detectable only in a part of gliomas restricting
the number of potentially treatable patients (Chi et al, 1997; Liu
et al, 2003, 2004b; Biernat et al, 2004). Owing to these limitations
of several glioma-associated antigens and the heterogeneity of
different types of malignant glioma (Chi et al, 1997; Nagane et al,
1997; Liang et al, 2005), the identification of additional target
structures for CTLs is required.
In the present study, we demonstrated that the transcription
factor SOX2 is overexpressed in the vast majority of malignant
gliomas, whereas expression in normal brain and other non-
malignant tissues is almost negligible. The expression of SOX2 in
glioma tissues, glioma cell lines as well as in the primary GBM cell
preparations DD-HT4, and DD-HT6559 was also verified at the
protein level. When investigating the suitability of SOX2 to serve as
a target antigen for T cells, we identified an immunogenic HLA-
A*0201-restricted peptide derived from SOX2, which proved to be
effective in activating tumour-directed CTL responses. These
results are in agreement with previous studies indicating the
immunogenicity of several SOX family members. Thus, SOX1,
SOX2, SOX3 and SOX21 as well as SOX4 were demonstrated to
elicit humoral immune responses in small cell lung cancer patients
(Gure et al, 2000; Friedman et al, 2004). In about one-third of
glioma patients, Ueda et al (2004) could detect anti-SOX6
antibodies but so far, no T-cell epitope was described. The
attractivity of SOX family members for T-cell-based immunother-
apy of tumours was documented by a recent report indicating that
SOX4 is overexpressed in lung carcinoma and can serve as a target
structure of CTLs (Friedman et al, 2004). More recently, we
identified SOX11 to be specifically overexpressed in the vast
majority of malignant gliomas (Weigle et al, 2005) and demon-
strated the generation of SOX11 peptide-reactive CTLs that were
capable of lysing HLA-matched glioma cell lines (Schmitz et al,
2007).
In summary, we characterised the transcription factor SOX2 as
a glioma-associated antigen that is abundantly and specifically
overexpressed in these brain tumours. In addition, we identified an
immunogenic HLA-A*0201-restricted T-cell epitope derived from
SOX2 that effectively activated tumour-directed CTLs. Our results
emphasise the suitability of this protein for a T-cell-based
immunotherapy of glioma patients.
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